CME INFORMATION

OVERVIEW OF ACTIVITY

The annual San Antonio Breast Cancer Symposium (SABCS) is unmatched in its significance with regard to the advancement of breast cancer treatment. It is targeted by many members of the clinical research community as the optimal forum in which to unveil new clinical data. This creates an environment each year in which published results from a plethora of ongoing clinical trials lead to the emergence of many new therapeutic agents and changes in the indications for existing treatments across all breast cancer subtypes. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of the rapidly evolving data sets in breast cancer. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest SABCS meeting, including expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists and other cancer clinicians in the formulation of optimal clinical management strategies for breast cancer.

LEARNING OBJECTIVE

- Appraise the interim safety data for capecitabine maintenance therapy after standard adjuvant chemotherapy for triple-negative early breast cancer.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentation, read the commentary and complete the Educational Assessment and Credit Form located at CME.ResearchToPractice.com.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

William J Gradishar, MD
Director, Breast Medical Oncology
Professor of Medicine
Robert H Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Kathleen I Pritchard, MD
Senior Scientist, Sunnybrook Research Institute
Medical Oncologist, Sunnybrook Odette Cancer Centre
Professor, Department of Medicine
Faculty of Medicine, University of Toronto
Toronto, Canada
Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests:


RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology, GenOMIC Health Inc, Novartis Pharmaceuticals Corporation and Sanofi-Aventis.

Last review date: March 2011
Expiration date: March 2012
Click here for SABCS papers on HER2-negative breast cancer

In 2001 the first results from the ATAC trial demonstrated the superiority of an AI (anastrozole) over tamoxifen. One year later a CALGB study showed an advantage for dose-dense AC → paclitaxel, and not long after that US Oncology proved that TC was better than AC and along the way the NSABP presented data on the Oncotype DX® assay to help select patients for adjuvant chemo. However, since the presentation of those important yet modest research advances, one could make the argument that not a whole lot else positive has happened in adjuvant treatment for the 80 percent of patients with HER2-negative breast cancer.

2010 didn’t do much to change this situation — at least that’s my conclusion after watching Alan Coates’ San Antonio “Year in Review” presentation on the management of early breast cancer. Of the 18 papers he discussed during this talk, none seem likely to lead to a meaningful change in the mortality of this disease. Perhaps the most provocative of the bunch highlighted by Dr Coates were the three neoadjuvant HER2-positive papers reviewed in a previous issue of this series. However, the HER2-negative papers that were “featured” made me long for a myeloma-like infusion of new agents that actually work.

Unfortunately, it’s not totally clear that this is on the horizon, especially if the data sets coming out in San Antonio are any indication. What we saw there were mainly a few legacy studies evaluating adjuvant chemotherapy, including:

1. Findings from another CALGB trial suggesting similar outcomes with four and six cycles of dose-dense paclitaxel or AC.

2. Two trials testing the addition of capecitabine to anthracycline/taxane regimens demonstrating questionable or no benefit, although two other related data sets suggested a slightly greater advantage with cape in triple-negative disease.

3. Early tolerability data on “maintenance” capecitabine after an anthracycline and/or a taxane — a strategy that makes sense, but no definitive efficacy data exist yet.

4. Another early safety report in a trial evaluating bevacizumab/chemotherapy in the adjuvant setting, but the recent negative results of two adjuvant trials of bev in colon cancer have perhaps dampened enthusiasm for this approach.
It’s a real disconnect to walk through the halls of San Antonio and see thousands of investigators presenting a seemingly endless array of data sets and still contemplate the fact that the current overall impact of this effort at a patient care level — especially in the most prevalent HER2-negative breast cancer subset — is relatively modest. It makes one wonder if we will soon see the payoff of this extensive investment in research and whether there is any way to change the trajectory of progress.

Next up on our final San Antonio issue of *5-Minute Journal Club*: Clinical trials in metastatic disease, including studies of combinations of biologic agents

Neil Love, MD

[Research To Practice](http://www.researchto实践.com)

Miami, FL

---

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Research To Practice designates each educational activity for a maximum of 0.25 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in each activity.

This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc, Novartis Pharmaceuticals Corporation and Sanofi-Aventis.

Research To Practice
One Biscayne Tower
2 South Biscayne Boulevard, Suite 3600
Miami, FL 33131

This email was sent to you by Dr Neil Love and Research To Practice. To unsubscribe to future email requests and announcements, [click here](mailto:unsubscribe@researchtopractice.com). To unsubscribe from all email communications, including CME/CNE activities sent by Research To Practice, [click here](mailto:unsubscribe@researchtopractice.com). To update your information on our current distribution lists, [click here](mailto:update@researchtopractice.com).

Presentation discussed in this issue


First Safety Data from a Randomized Phase III (CIBOMA/2004-01/GEICAM 2003-11) Trial Assessing Adjuvant Capecitabine Maintenance Therapy After Standard Chemotherapy for Triple-Negative Early Breast Cancer

Study Design

Accrual: 816 (Open)

<table>
<thead>
<tr>
<th>Eligibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operable node-positive (or node-negative with tumor diameter ≥1 cm)</td>
</tr>
<tr>
<td>Centrally confirmed TNBC</td>
</tr>
<tr>
<td>No evidence of metastatic disease</td>
</tr>
<tr>
<td>6-8 cycles of prior anthracycline and/or taxane-based chemo or 4 cycles of doxorubicin/cyclophosphamide (for node-negative disease) in the (neo)adjuvant setting</td>
</tr>
</tbody>
</table>

Safety data reported for first 400 patients (pts)

- **Capecitabine**
  - 1,000 mg/m² BID d1-14
  - q3wks x 8

- **Observation**


---

Treatment-Related Grade 3/4 Adverse Events*

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Capecitabine (n = 207)</th>
<th>Observation (n = 193)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hand-foot syndrome†</td>
<td>17.4%</td>
<td>—</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>2.9%</td>
<td>—</td>
</tr>
<tr>
<td>Fatigue</td>
<td>1.9%</td>
<td>—</td>
</tr>
<tr>
<td>Vomiting</td>
<td>1.0%</td>
<td>—</td>
</tr>
<tr>
<td>Nail changes</td>
<td>1.0%</td>
<td>—</td>
</tr>
<tr>
<td>Elevated bilirubin</td>
<td>1.0%</td>
<td>—</td>
</tr>
<tr>
<td>Irregular menses</td>
<td>0.5%</td>
<td>7.8%</td>
</tr>
</tbody>
</table>

* Grade 3/4 events occurring in ≥2 patients in either treatment arm;
† Grade 3 only

## Proportion of Cycles with Treatment Discontinuation Due to Toxicity

<table>
<thead>
<tr>
<th>Cycles, %</th>
<th>N = 1,440</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toxicity</td>
<td>12.2%</td>
</tr>
<tr>
<td>Hand-foot syndrome</td>
<td>7.4%</td>
</tr>
<tr>
<td>Neutrophils/granulocytes</td>
<td>1.2%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>1.1%</td>
</tr>
<tr>
<td>Mucositis/stomatitis</td>
<td>0.5%</td>
</tr>
<tr>
<td>Leukocytes</td>
<td>0.4%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>0.3%</td>
</tr>
</tbody>
</table>


## Selected Reasons for Discontinuation

<table>
<thead>
<tr>
<th>Rationale, n (%)</th>
<th>Capecitabine (n = 207)</th>
<th>Observation (n = 193)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Withdrawal request by pt</td>
<td>16 (7.8%)</td>
<td>2 (1.0%)</td>
</tr>
<tr>
<td>Unacceptable toxicity</td>
<td>15 (7.2%)</td>
<td>1 (0.5%)</td>
</tr>
<tr>
<td>Disease relapse</td>
<td>5 (2.4%)</td>
<td>7 (3.7%)</td>
</tr>
<tr>
<td>Tx interruption &gt;3 wks</td>
<td>4 (1.9%)</td>
<td>—</td>
</tr>
<tr>
<td>Death</td>
<td>3 (1.4%)</td>
<td>2 (1.0%)</td>
</tr>
<tr>
<td>Protocol deviation</td>
<td>2 (1.0%)</td>
<td>1 (0.5%)</td>
</tr>
<tr>
<td>Lost to follow-up</td>
<td>1 (0.5%)</td>
<td>1 (0.5%)</td>
</tr>
</tbody>
</table>

Author Conclusions

- The safety profile of adjuvant capecitabine as maintenance therapy is consistent with its known toxicity profile.
- More than 75% of patients are able to complete their treatment as planned, with approximately 15% of patients discontinuing due to toxicity or patient withdrawal.
- Ongoing recruitment with an accrual of 876 patients is planned.


Investigator Commentary: Maintenance Capecitabine After Adjuvant Chemotherapy for Triple-Negative Breast Cancer

The CIBOMA/GEICAM investigators demonstrated that administering maintenance capecitabine after standard adjuvant chemotherapy for patients with triple-negative early breast cancer was not associated with excessive capecitabine-associated side effects, and hand-foot syndrome and diarrhea were the most common adverse events. This was a preliminary report, and efficacy data are not yet available.

Interview with William J Gradishar, MD, January 4, 2011

The Swiss have been investigating metronomic cyclophosphamide and methotrexate as maintenance therapy in the adjuvant setting. We were interested in joining the Swiss study, but we were unhappy about approaching patients to undergo a year of maintenance therapy.

I have used capecitabine a lot as a single agent for metastatic disease, and it may not be a “slam dunk” to administer it as maintenance therapy, even though it’s orally administered. Patients must be carefully watched because they “soldier on” and do not always report symptoms. Using maintenance capecitabine will require careful management and watching the dose closely. However, if this approach turns out to be positive, then we will all be using maintenance therapy.

Interview with Kathleen I Pritchard, MD, December 30, 2010